modelDexibuprofen
Extends from Pharmacolibrary.Drugs.ATC.M.M01AE14.
Information
| name: | Dexibuprofen | |
| ATC code: | M01AE14 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 0.14 | L |
| clearance: | 0.053 | L/h/kg |
| other parameters in model implementation | ||
Dexibuprofen is the S(+)-enantiomer of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain, inflammation, and fever in conditions such as rheumatoid arthritis and osteoarthritis. It is approved and used in Europe and other countries, but not in the United States.
Pharmacokinetics
Pharmacokinetic parameters estimated in healthy adult volunteers after single oral dose administration.
References
Yoon, JS, et al., & Lee, JS (2008). The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection. British journal of clinical pharmacology 66(6) 854–860. DOI:10.1111/j.1365-2125.2008.03271.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19032727
Sánchez-López, E, et al., & García, ML (2017). New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine : nanotechnology, biology, and medicine 13(3) 1171–1182. DOI:10.1016/j.nano.2016.12.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27986603
Mandal, U, et al., & Pal, TK (2008). Bioequivalence study of two formulations containing 400 mg dexibuprofen in healthy Indian subjects. Arzneimittel-Forschung 58(7) 342–347. DOI:10.1055/s-0031-1296517 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18751500
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)